Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

4.920 -0.190 (-3.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,144,699
Open 5.150
Bid (Size) 4.950 (40)
Ask (Size) 4.960 (3)
Prev. Close 5.110
Today's Range 4.891 - 5.187
52wk Range 1.891 - 5.820
Shares Outstanding 287,686,199
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
From AbCellera Biologics Inc.
Via Business Wire

Performance

YTD
+62.4%
+62.4%
1 Month
+43.4%
+43.4%
3 Month
+90.0%
+90.0%
6 Month
+46.4%
+46.4%
1 Year
+52.3%
+52.3%

More News

Read More
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today
Via The Motley Fool
Earnings Scheduled For May 8, 2025
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
From AbCellera Biologics Inc.
Via Business Wire
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Reports Q1 2025 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Participate at Upcoming Investor Conferences in May and June
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
AbCellera Reports Full Year 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Participate at Upcoming Investor Conferences in March
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at Upcoming Investor Conferences in December and January
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
AbCellera Reports Q3 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at Upcoming Investor Conferences in November 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
From AbCellera Biologics Inc.
Via Business Wire

Frequently Asked Questions

Is AbCellera Biologics Inc. - Common Shares publicly traded?
Yes, AbCellera Biologics Inc. - Common Shares is publicly traded.
What exchange does AbCellera Biologics Inc. - Common Shares trade on?
AbCellera Biologics Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AbCellera Biologics Inc. - Common Shares?
The ticker symbol for AbCellera Biologics Inc. - Common Shares is ABCL on the Nasdaq Stock Market
What is the current price of AbCellera Biologics Inc. - Common Shares?
The current price of AbCellera Biologics Inc. - Common Shares is 4.920
When was AbCellera Biologics Inc. - Common Shares last traded?
The last trade of AbCellera Biologics Inc. - Common Shares was at 07/28/25 04:00 PM ET
What is the market capitalization of AbCellera Biologics Inc. - Common Shares?
The market capitalization of AbCellera Biologics Inc. - Common Shares is 1.42B
How many shares of AbCellera Biologics Inc. - Common Shares are outstanding?
AbCellera Biologics Inc. - Common Shares has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.